In a landmark decision, the U.S. Food and Drug Administration (FDA) has begun removing long-standing “black box” warnings from hormone replacement therapy (HRT) products used for menopause care. The move was announced by the U.S. Department of Health and Human Services (HHS) and is intended to correct more than 20 years of confusion, fear, and misinformation that kept many women from receiving care that could improve their quality of life.
The announcement was made by Health and Human Services Secretary Robert F. Kennedy Jr. and FDA Commissioner Marty Makary, M.D., M.P.H., during a press event attended by more than 200 people, including key members of the administration.
Why Does This Change To HRT Matter?
For decades, HRT has helped women manage the symptoms of menopause, which naturally occurs as the ovaries produce less estrogen and progesterone. These hormones support everything from bone strength to heart function, sleep, mood, and cognitive performance. Many women experience hot flashes, night sweats, sleep disruption, and bone loss during this stage of life.
In the early 2000s the FDA added serious warning labels based on a study that was widely misinterpreted. The study involved women whose average age was 63, which is beyond the typical age of menopause onset, and it used hormone formulations that are no longer common today. After the warnings were added, use of HRT dropped and many women missed out on care that could have supported their long-term wellbeing.
What Did the FDA Review?
After an extensive review of medical literature, expert panel discussions, and a public comment period, the FDA determined that the old warnings overstated risks such as cardiovascular disease, breast cancer, and dementia. Those references are now being removed from product labeling. The agency will keep a warning related to endometrial cancer for estrogen-only systemic products, which applies specifically to women without a uterus.
Secretary Kennedy said, “Today, we are standing up for every woman who has symptoms of menopause and is looking to know her options and receive potentially life-changing treatment. For more than two decades, bad science and bureaucratic inertia have resulted in women and physicians having an incomplete view of HRT. We are returning to evidence-based medicine and giving women control over their health again.”
FDA Commissioner Makary added, “Women and their physicians should make decisions based on data, not fear.”
What Does Current Research on HRT Show?
Today’s evidence shows significant potential benefits when women start HRT within 10 years of menopause onset or before age 60. Research has shown that starting at the right time may:
- Reduce all-cause mortality
- Reduce the risk of cardiovascular diseases by up to 50 percent
- Reduce the risk of Alzheimer’s disease by up to 35 percent
- Reduce bone fractures by 50 to 60 percent
The FDA’s updated labeling will now reflect this timing guidance.
What Other Healthcare Options Were Approved?
Alongside the change in warnings, the FDA also approved two new menopause-related medications:
- A generic version of Premarin (conjugated estrogens), expected to improve affordability and access
- A new non-hormonal option for women who choose not to use HRT, designed to help with moderate to severe hot flashes
What Does This Mean For You?
Menopause is a natural part of life, and women deserve clear options and supportive care. At Liquid Mobile, we offer personalized Hormone Replacement Therapy designed to help women feel better, sleep better, and stay active through this transition.
How Do I Get Started with HRT?
If you are experiencing symptoms of menopause or want to learn more about your options, Liquid Mobile is here to help. Our trusted professionals will meet with you one on one, either in clinic or via telehealth, to guide you through your choices and create a plan that fits your lifestyle.
Click here to schedule a consultation today or call 855-954-7843 and take back control of your wellbeing.